---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040499"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:57:40.876378+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences reports Q3 2023 net loss of $2.82M; cash $4.27M; advances psychedelic pipeline

## Summary
- Net loss of $2.82M ($1.30 per share) vs $2.60M ($1.46 per share) in Q3 2022.
- Cash and cash equivalents of $4.27M as of Sept 30, 2023.
- Granted two US patents for EVM301 Series and EB-373; filed six non-US applications.
- Completed manufacturing of EB-373; preclinical data show oral bioavailability and safety.
- AI drug discovery engine Psybrary surpassed 1,000 compounds analyzed.

## SEC filing metadata
- accession: 0001493152-23-040499
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315223040499/0001493152-23-040499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315223040499/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040499
- JSON: https://secwatch.observer/filing/0001493152-23-040499.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040499.txt

## Key facts
- Earnings Releases
  Enveric Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315223040499/0001493152-23-040499-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.